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Abstract
Background: Gastric cancer exhibits various degrees of fluorine F-18 fluorodeoxyglucose (18F-FDG) uptake on
positron emission tomography/computed tomography (PET/CT). We evaluated the relationship between 18F-FDG
uptake and the presence/absence of metastasis in individual lymph nodes (LN) on a one-to-one basis.
Methods: We analyzed 21 patients with gastric cancer. We injected 18F-FDG intravenously in the morning, and
gastrectomy with LN dissection was performed in the afternoon of the same day. Radiation doses were measured
at each LN using a well-type counter, and we then compared 18F-FDG uptake, the shortest diameter, and pathological
examination results for each LN.
Results: In our study, 906 LNs were analyzed, including 115 metastatic LNs. Metastatic LNs showed significantly higher
18F-FDG uptake (P < 0.0001), and were significantly enlarged (P < 0.0001). The receiver operating characteristics (ROC)
curve had a larger area under the curve (0.71) for 18F-FDG uptake than for the shortest LN diameter (0.60). Considering
histology, the ROC curve for intestinal type adenocarcinoma had a larger area under the curve than that for diffuse
type (0.75 vs 0.61).
Conclusions: F-FDG uptake is potentially a more useful variable than LN diameter for discriminating between LN with
and without metastasis, especially in intestinal type gastric cancer cases.
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Background
In gastric cancer, lymph node (LN) metastasis is an im-
portant prognostic factor [1, 2]. Among patients with R0
resection for gastric cancer, LN status was the most im-
portant independent prognostic factor, followed by the pT
category, surgical complication, and distant metastasis [1].
Therefore, accurate knowledge of LN status would be
helpful for predicting prognosis and planning the extent
of lymphadenectomy. Enhanced computed tomography
(CT), which is routinely performed to evaluate LN metas-
tasis in gastric cancer, has a sensitivity of 80.0 % and a spe-
cificity of 77.8 %, based on the size of LN [3]. However,
Monig et al. reported LN size to be an unreliable indicator
of LN metastasis in patients with gastric cancer [4]. As
compared to CT scans, fluorine F-18 fluorodeoxyglucose
positron emission tomography and computed tomography
(18F-FDG PET/CT) shows lower sensitivity and higher
specificity for evaluating regional LN metastasis [5]. How-
ever, low sensitivity may result from low spatial resolution
of both PET scanning and PET/CT scan [3, 5–7].
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Considering the difficulty to diagnose LN metastasis pre-
operatively, prophylactic LN dissection is regarded as es-
sential to curative resection for gastric cancer, resulting in
the dissection of non-metastatic LNs.
18F-FDG has been used for not only preoperative diagno-
sis but also intraoperative diagnosis and navigation surgery
using intraoperative gamma probe [8–10]. This navigation
system during gastric cancer surgery can be planned, if the
radiation dose of 18F-FDG shows nodal involvement pre-
cisely. To our knowledge, there are no reports comparing
pathological findings and 18F-FDG uptake on a one-to-one
basis.
The aim of this study was to clarify the diagnostic power
of 18F-FDG by investigating the one-to-one relationship




Study patients were recruited between July 2012 and
September 2013 at the Department of Gastrointestinal
Surgery, the University of Tokyo Hospital, Japan, for a pro-
spective pilot study. Criteria for inclusion in this study were
(1) adenocarcinoma of the stomach confirmed by patho-
logical examination, (2) diagnosis of advanced gastric
cancer based on preoperative CT scan or endoscopic exam-
ination results, (3) necessity of gastrectomy for curative or
palliative intent, (4) age 85 years or younger, (5) normal
renal function, and (6) European clinical oncology group
performance status (ECOG-PS) ≦1. Exclusion criteria were
(1) diabetes mellitus, (2) any severe ongoing comorbidity,
(3) prior malignant diseases, and (4) synchronous malig-
nancies other than gastric cancer. For patients who meet
these criteria, we injected 18F-FDG on the day of surgery,
took 18F-FDG PET/CT in the morning, and measured radi-
ation dose of each LN after harvesting LNs by surgery in
the afternoon. We only included patients with advanced
gastric cancer since 18F-FDG PET/CT suffers from low de-
tection rate of LN involvement for early gastric cancer [11].
Ethics statement
The scientific protocol was approved by the local ethics
committee (Graduate School of Medicine and Faculty of
Medicine, the University of Tokyo, no. 3799). Written
informed consent for participating this study and pub-
lishing was obtained from all participants. This trial was
registered in the UMIN Clinical Trial Registry (UMIN
000013934, http://www.umin.ac.jp/ctr/).
FDG-PET/CT study
In the morning of the day of gastrectomy, 18F-FDG was
injected intravenously 3–4 h prior to surgery, and PET/
CT scans were obtained. Patients fasted for at least 5 h be-
fore undergoing FDG-PET, and a blood sugar level under
150 mg/dL was required. Each patient received 296 MBq
of intravenous FDG. Imaging was then performed 50 min
later using an Aquiduo PET/CT scanner (Toshiba Medical
Systems, Otawara, Japan). This scanner contains 24,336
lutetium oxyorthosilicate (LSO) crystals in 39 detector
rings and has an axial field of view of 16.2 cm and 82
transverse slices with a 2.0 mm thickness. The intrinsic
full width at half-maximum (FWHM) spatial resolution in
the center of the field of view is ~4.3 mm, and the FWHM
axial resolution is 4.7 mm. The sinogram was acquired in
the three-dimensional mode. The CT scan was performed
with a tube current of 50 mA and a tube voltage of 120 kV
for attenuation correction, and one 2.5-min emission scan
per position was acquired. Images were reconstructed using
Fourier rebinning ordered subset expectation maximization
iterative reconstruction, with two iterations and eight sub-
sets, and a 4-mm FWHM Gaussian filter was applied. The
data were collected in a 128 × 128 × 41 matrix with a voxel
size of 2.0 × 2.0 × 4.0 mm.
PET/CT images were visually evaluated by two of the
authors, both of whom are experienced nuclear medicine
physicians (MT and KK). The maximum activity concen-
tration within the lesions of interest was determined and
expressed as the maximal standardized uptake value (SUV
max). All SUV measurements were normalized for patient
body weight and for the time elapsed from injection until
data acquisition. If the PET/CT scan showed distant me-
tastasis, we reviewed the indications for the scheduled
gastrectomy. We determined the sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) of 18F-FDG PET as described in a previous
report [7]. We classified regional LNs into three groups:
LNs along the lesser curvature, LNs along the greater
curvature, and other regional LNs (LNs in suprapancreatic
area and hepatoduodenal ligament). LNs were considered
positive or negative on the basis of the group as a whole.
Radiation dose measurements for individual LNs
After 18F-FDG PET/CT scan in the morning, gastrectomy
with LN dissection was performed in the afternoon. All
LNs were harvested from the surgical specimen before
formalin fixation. We measured the radiation dose of each
LN using a CAPRAC-t well-type counter (Capintec, Inc.,
Pittsburgh, PA, USA) with the energy window set at
464.7–557.3 keV before formalin fixation and staining.
The energy window was determined by the FWHM peak
of the 511 keV radiation spectrum, in order to precisely
measure the radiation dose of 18F-FDG. Since it took 40–
50 s to prepare for the radiation dose measurement in
each LN, we set the count time at 30 s to assure that the
time between the first LN and the last LN measurement
would be within the half-life of 18F-FDG (109.8 min). In
addition, we determined the weight and shortest diameter
of each LN before fixation. To assess 18F-FDG uptake of
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each LN by well-type counter, the modified standardized
uptake value of each LN (modified SUV) was calculated
using the following formula: modified SUV =CCF ×Cdc/
(di/w), where CCF is the cross-calibration factor, Cdc is the
decay-corrected tracer tissue concentration normalized
for the time elapsed from 18F-FDG injection until data ac-
quisition (in counts per second per gram), di is the
injected dose (in becquerels), and w is the patient’s body
weight (in grams). CCF is the ratio of the radioactivity
(count per second) measured with the well-type counter
to those (in becquerels) obtained with the dose calibrator.
In this study, we determined CCF to be 5.8 based on our
measurements using test tubes filled with 18F-FDG solu-
tion, the dose calibrator, and the well-type counter. We
also compared the diagnostic usefulness of LN size and
18F-FDG uptake.
Surgical specimens including the excised stomach and
LNs were examined by an experienced pathologists (KM,
HA, and TU) with no knowledge of either the 18FDG-
PET/CT findings or the radiation dose measurements. We
conducted the tumor staging according to the Union for
International Cancer Control (UICC) TNM staging sys-
tem for the stomach [12]. Each LN was examined employ-
ing 2 mm-spaced slices using hematoxylin-eosin-stained
sections to avoid missing small focal metastases. The gas-
tric cancers were histologically classified into two groups
according to the Lauren classification system [13]. Well
and moderately differentiated tubular adenocarcinoma,
papillary adenocarcinoma, and solid type poorly differenti-
ated adenocarcinoma were classified as intestinal type
carcinomas. Non-solid type poorly differentiated adeno-
carcinoma, signet ring cell carcinoma, and mucinous car-
cinoma were classified as diffuse-type carcinomas.
Statistical analysis
All statistical analyses were carried out using JMP 10.0.2
software (SAS institute, Cary, NC, USA). Differences in
histological type as categorical variables were compared
between metastasis-positive and metastasis-negative LNs
employing the chi-square test. The Wilcoxon test was ap-
plied for continuous variables including modified SUV,
the shortest LN diameter, and the time elapsed from 18F-
FDG injection until data acquisition. Differences were
considered significant at P < 0.05. The receiver operating
characteristics (ROC) curves for the shortest LN diameter
and modified SUV were used to discriminate LN metasta-
sis from other findings. For this purpose, the area under
each curve was used to measure the discriminatory ability
of the model.
Results
Patient characteristics and PET/CT findings
In total, 21 patients were recruited for this study, and
906 LNs were harvested. Characteristics of the 21 pa-
tients are summarized in Table 1. Intestinal type was the
main histopathology, being seen in 15 cases, diffuse type
in the other 6. As for primary lesion, median SUV max
was 7.1, and these values were higher in the intestinal
type group (8.0 vs 6.4) on PET/CT scan. Median blood
sugar was 95.0 mg/dL in the intestinal type group and
97.5 mg/dL in the diffuse-type group. Upon primary
tumor staging of these patients, five of six (83 %) in the
diffuse-type group were diagnosed as having pT4a. D2
lymphadenectomy was performed in 11 patients with in-
testinal type and two with diffuse-type gastric cancer. Dis-
tant LN sampling was performed in four patients because
preoperative or intraoperative findings had indicated LN
Table 1 Characteristics of the 21 patients and result of PET/CT
Total Intestinal type Diffuse type
Characteristics n = 21 n = 15 n = 6
Sex: male/female 16/5 10/5 6/0
Median age, years (range) 70 (41–81) 69 (41–81) 76 (62–81)
Operations: TG/DG/PG 11/8/2 8/6/1 4/1/1
Dissection: D0/D1/D1+/D2 1/2/5/13 1/1/2/11 0/1/3/2
Locus: upper/middle/lower 9/9/3 4/9/2 5/0/1
T status: pT1b/pT2/pT3/pT4a 3/4/6/8 2/4/6/3 1/0/0/5
N status: pN0/pN1/pN2/pN3 5/7/3/6 5/5/2/3 0/2/1/3
pStage: I/II/III/IV 2/9/5/5 1/9/2/3 1/0/3/2
SUV max of primary lesion on PET/CT
Median (range) 7.1 (2.4-24.1) 8.0 (2.4-24.1) 6.4 (3.2-11.6)
SUV max of LNs on PET/CT
Median (range) 4.7 (1.6-5.5) 3.15 (1.6-4.9) 5.5 (5.5)
TG total gastrectomy, DG distal gastrectomy, PG proximal gastrectomy, SUV standard uptake value, LN lymph node, PET/CT positron emission
tomography/computed tomography
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enlargement. Five patients with stage IV disease under-
went palliative gastrectomy for anemia or symptoms of
obstruction. The median primary tumor size was 6.5 cm
(range, 2.3-16.5 cm). The primary lesion was larger in the
diffuse-type group (11.6 vs 5.6 cm). Among 16 cases with
LN metastases, 5, including 4 with intestinal type and 1
with diffuse type, had PET-positive LNs. The median SUV
max of PET-positive LNs was 4.7. The sensitivity, specifi-
city, PPV, and NPV of preoperative PET/CT were 24, 100,
100, and 57 %, respectively.
Result of radiation dose measurement by well-type
counter
The 906 harvested LNs included 115 with metastases
(Table 2). The median time between 18F-FDG injection
and measurement of 18F-FDG uptake using the well-type
counter was 444 min (range 343-527 min). Measurement
by the well-type counter revealed significantly higher
modified SUV among metastatic LNs than non-metastatic
LNs (Table 2). The time between 18F-FDG injection and
the completion of LN resection was 364 min in the node-
positive group and 336 min in the node-negative group.
The median blood sugar levels in node-positive and node-
negative patients were 96 and 92 mg/dl, respectively. The
time elapsed from 18F-FDG injection until data acquisition
by well-type counter was 435 min for the metastasis-
positive LNs and 446 min for the metastasis-negative LNs
(P = 0.0003). Metastatic LNs were also significantly en-
larged as compared to non-metastatic LNs (Table 2).
Figure 1 shows the ROC curve for modified SUV used to
distinguish between LNs with and without metastasis. The
area under the curve for modified SUV was 0.71 for meta-
static LNs. Using a cutoff of 2.62, the sensitivity, specifi-
city, PPV, and NPV were 77, 60, 24, and 94 %,
respectively. On the other hand, the area under the curve
for the shortest LN diameter was 0.60. Using a cutoff of
7.0 mm, the sensitivity, specificity, PPV, and NPV were 39,
77, 21, and 89 %, respectively. The area under the curve
was 0.75 in cases with intestinal adenocarcinoma (Fig. 2)
and 0.61 in those with diffuse adenocarcinoma (Fig. 3).
Using a cutoff of 2.65 in the intestinal type group, the sen-
sitivity, specificity, PPV, and NPV were 80, 65, 23, and
96 %, respectively. In the diffuse-type group, the sensitiv-
ity, specificity, PPV, and NPV were 89, 41, 26, and 94 %
with a cutoff of 1.98.
Discussion
To the best of our knowledge, this is the first one-to-one
comparison between the 18F-FDG uptake and patho-
logical status of individual LNs. Metastatic LNs showed
significantly higher modified SUV than non-metastatic
LNs using well-type counter. The area under the ROC
curve for modified SUV was larger than that for the
shortest LN diameter, indicating 18F-FDG uptake to be a
better indicator than CT scan findings for detecting LN
metastasis of gastric cancer. Micrometastasis such as
isolated cluster-type tumor cells is frequently found in
gastric cancer [14], therefore, accurate diagnosis of LN
involvement by size is considered to be difficult. Since
18F-FDG uptake reflects the metabolic status of the le-
sion, this modality has been anticipated to be useful for
the assessment of metastasis.
The area under the curve was larger for intestinal type
adenocarcinoma than for the diffuse histological type.
Intestinal type gastric cancer expresses more GLUT-1
than diffuse type, and this is associated with the fact that
intestinal type gastric cancer shows higher SUV max
than diffuse type on 18F-FDG PET/CT [15]. Difference
of GLUT-1 expression may affect higher detection rate
of 18F-FDG uptake for LN metastasis for intestinal type
adenocarcinoma by well-type counter.
As for FDG-PET/CT, low sensitivity and high specifi-
city of PET/CT scan for detecting LN metastasis were
also demonstrated in current study. There are some re-
ports about the sensitivity and specificity of 18F-FDG
PET or PET/CT for detecting LN metastasis of gastric
Table 2 Characteristics of 906 LNs in the 21 patients and measurement results by well-type counter
LN with metastasis LN without metastasis P value
Characteristics n = 115 n = 791
Modified SUV <0.001
Median (range) 3.50 (0–9.52) 2.06 (0–14.18)
Histology of primary lesion 0.001
Intestinal 71 605
Diffuse 44 186
Time from 18F-FDG injection until data acquisition (min) 0.0003
Median (range) 435 (343–517) 446 (347–527)
Shortest LN diameter (mm) 0.0005
Median (range) 6 (2–19) 5 (1–16)
LN lymph node, 18F-FDG fluorine F-18 fluorodeoxyglucose
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cancer [3, 6, 7, 16]. These studies included limitation of
spatial resolution that 18F-FDG uptake in perigastric LN
and inflammatory gastric wall or primary lesion could
not be distinguished. Additionally, partial volume effect
might affect low sensitivity of PET/CT scan. Since our
one-to-one comparison was not disturbed by spatial
resolution, our study revealed realistic diagnostic power
of 18F-FDG for detecting LN metastasis of gastric
cancer.
Recently, navigation surgery using a radioactive agent
has been considered. Navigation surgeries are beneficial in
terms of precise cancer detection, leading to avoidance of
unnecessary resection. Sentinel node navigation surgery is
focused on lymphatic drainage and is based on the idea
that the sentinel node is the first possible site of LN me-
tastasis [17, 18]. Navigation surgery which focuses on the
metabolism of cancer cells has also been investigated [19].
Uptake of radioactive agent is detected using gamma
probe without harvesting LNs; therefore, this method was
expected to prevent unnecessary LN dissection. Naviga-
tion surgery using 18F-FDG has been reported for several
malignancies [8–10]. In these series, 18F-FDG was injected
preoperatively, and focal accumulation of 18F-FDG was
detected with an intraoperative gamma probe. We
planned this pilot study for navigation surgery using 18F-
FDG in case with gastric cancer, but its sensitivity and
specificity were not sufficient. Even though sentinel navi-
gation surgery for early gastric cancer has 97.5 % of detec-
tion rate and 99 % of accuracy for LN evaluation, its
efficacy remains to be clarified [17, 18]. Other tracers have
been investigated for diagnostic application in some ma-
lignancies [20–23]; therefore, navigation surgery using
these new tracers might be feasible.
This study has limitations. The first limitation was the
time elapsed from 18F-FDG injection until radiation dose
measurement. Considering the half-life of 18F-FDG
(109.8 min), the time elapsed from 18F-FDG injection until
data acquisition was rather long (444 min). The time
elapsed from 18F-FDG injection until data acquisition was
significantly longer for metastasis-negative than for
metastasis-positive LNs. Extent of LN dissection may in-
fluence the length of this time period. Since the D2
lymphadenectomy group had more harvested LNs, it took
a longer time to measure the radiation dose of all
Fig. 1 The ROC curve for modified SUV and the shortest LN
diameter. The ROC curve for modified SUV had a larger area under
the curve (0.71) than that for the shortest LN diameter (0.60)
Fig. 2 The ROC curves for modified SUV in intestinal type
carcinoma. The area under the curve for this parameter is 0.75
Fig. 3 The ROC curves for modified SUV in diffuse-type carcinoma.
The area under the curve for this parameter is 0.61
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harvested LNs in this group. 18F-FDG uptake in tumors
does not peak until approximately 4–5 h after FDG injec-
tion [19], but some of the LNs in this study showed low
counts at measurement using the well-type counter. Al-
though we normalized our data for the time factor, it may
still have affected our results. We used the modified SUV
to represent 18F-FDG uptake. This conversion facilitates
correcting for various injected FDG doses and patient
body masses, but some of the LNs in this study showed
low counts at measurement using the well-type counter.
Although we normalized our data for the time factor, our
results may still have been affected. CCF was obtained by
measuring activity in test tubes filled with 18F-FDG solu-
tion using the dose calibrator and the well-type counter,
in which the radioactivity ranged from 1094 to 4 cps. The
calculated CCF fluctuated more widely at the lower mea-
sured activities. Therefore, this CCF fluctuation may be
one of the causes of the overlap between the positive LN
and negative LN activities observed in this study. We did
not investigate the correlation of SUV max on preopera-
tive PET scans and modified SUV in postoperative ana-
lysis. Other indexes such as percent injected dose should
also be investigated. The second limitation was the limited
number of patients. This may affect especially low sensi-
tivity of PET/CT scan.
Conclusions
In conclusion, 18F-FDG uptake is a more useful variable
than the shortest LN diameter for detecting LN metastasis
of gastric cancer, especially in cases with intestinal type
adenocarcinoma. However, its sensitivity and specificity
were not sufficient to be applied clinically as navigation
yet. Further investigation should be planned for navigation
surgery.
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